We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Corporation (WAT - Free Report) reported first-quarter 2025 non-GAAP earnings of $2.25 per share, beating the Zacks Consensus Estimate by 1.35% and increasing 1.8% year over year.
Net sales of $662 million topped the Zacks Consensus Estimate by 1.08%. The figure increased by 4% on a reported basis and 7% on a constant currency (cc) basis year over year.
Waters saw a strong first quarter, with sales exceeding the high end of its guidance range. Growth momentum continued across all three major regions-Asia, Americas and Europe- driven by robust demand in the Pharma and Industrial sectors.
Liquid chromatography and mass spec sales grew in double digits, marking positive growth in these key end markets.
Waters Corporation Price, Consensus and EPS Surprise
WAT operates under two organized segments: Waters and TA.
The Waters segment (88.8% of net sales) generated sales worth $587.3 million, up 4.5% and 8% on a year-over-year and CC basis, respectively. Sales in the TA segment were $74.4 million (11.2%), reflecting a year-over-year decline of 0.7%, but increasing 1% at cc.
Products & Services: The division comprises three segments: Instruments, Services, and Chemistry.
Instruments sales (39.7% of net sales) were $262.9 million, increased 8.7% on a year-over-year basis and 11% at cc.
Services registered sales (39.5% of net sales) worth $261.2 million, climbing a mere 0.2% year over year and 3% at cc.
Chemistry sales (20.8% of net sales) were $137.6 million, growing 2.6% year over year and 5% at cc.
The Services and Chemistry segments jointly generated recurring revenues of $398.8 million, up 1% year over year and 4% at cc.
Markets: Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic.
The Pharmaceutical market (59.1% of net sales) generated sales of $391.1 million, which increased 4.5% on a year-over-year and 8% at cc.
The Industrial market’s (27.5% of net sales) sales were $203.4 million, up 4.1% year over year and 6% at cc.
The Government & Academic market (10.2% of net sales) generated $67.3 million in sales, which remained flat year over year and increased 3% at cc.
Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia (33.4% of net sales) generated $220.8 million in sales, up 6.4% and 13% on a year-over-year and cc basis, respectively.
Sales in the Americas (38.6% of net sales) generated $255.5 million, which increased 6% in both year-over-year and cc terms.
Europe (28% of net sales) generated $185.4 million in sales, which decreased 1.4% year over year but increased 1% at cc.
WAT’s Q1 Operating Details
In the first quarter of 2025, non-GAAP selling and administrative expenses were $170.1 million, up 6% year over year. As a percentage of net sales, the figure expanded 50 basis points (bps) on a year-over-year basis.
Research and development spending of $46 million increased 7.7% year over year. As a percentage of net sales, the figure expanded 20 bps year over year.
The adjusted operating margin was 25.5%, which contracted 150 bps year over year.
Waters Balance Sheet & Cash Flow
As of March 29, 2025, cash, cash equivalents were $382.9 million, up from $325.4 million as of Dec. 31, 2024.
Waters generated cash from operations of $259.6 million in the reported quarter, down from $262.9 million in the year-ago quarter.
WAT recorded a free cash flow of $233.8 million in the first quarter of 2025.
WAT Raised Guidance
For the second quarter of 2025, Waters expects non-GAAP earnings of $2.88-$2.98 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
The Zacks Consensus Estimate for earnings is pegged at $2.93 per share, down by a penny over the past 30 days but indicates 11.4% growth from the figure reported in the year-ago quarter.
Waters anticipates sales to grow 5-7% on a cc basis after adequately discounting recent policy developments in the United States.
On a reported basis, total sales growth is predicted to be in the range of 4-6% backed by the strong first quarter and tailwinds from favorable forex.
The Zacks Consensus Estimate for revenues is pegged at $746.9 million, suggesting 5.42% year-over-year growth.
For 2025, Waters anticipates non-GAAP earnings between $12.75 per share and $13.05 per share.
The Zacks Consensus Estimate for earnings is pegged at $12.85 per share, up by a penny over the past 30 days, indicating an 8.4% increase from the figure reported in 2024.
On a reported basis, total sales are suggested to improve by 4.0 – 6.0% while at cc sales is expected to increase between 5% and 7%.
ANI Pharmaceuticals is set to report its first-quarter 2025 results on May 9. Acurx Pharmaceuticals is set to report first-quarter 2025 results on May 13. Agenus is set to report its first-quarter 2025 results on May 12.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
Waters Corporation (WAT - Free Report) reported first-quarter 2025 non-GAAP earnings of $2.25 per share, beating the Zacks Consensus Estimate by 1.35% and increasing 1.8% year over year.
Net sales of $662 million topped the Zacks Consensus Estimate by 1.08%. The figure increased by 4% on a reported basis and 7% on a constant currency (cc) basis year over year.
Waters saw a strong first quarter, with sales exceeding the high end of its guidance range. Growth momentum continued across all three major regions-Asia, Americas and Europe- driven by robust demand in the Pharma and Industrial sectors.
Liquid chromatography and mass spec sales grew in double digits, marking positive growth in these key end markets.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
Waters’ Q1 Top Line in Detail
WAT operates under two organized segments: Waters and TA.
The Waters segment (88.8% of net sales) generated sales worth $587.3 million, up 4.5% and 8% on a year-over-year and CC basis, respectively. Sales in the TA segment were $74.4 million (11.2%), reflecting a year-over-year decline of 0.7%, but increasing 1% at cc.
Products & Services: The division comprises three segments: Instruments, Services, and Chemistry.
Instruments sales (39.7% of net sales) were $262.9 million, increased 8.7% on a year-over-year basis and 11% at cc.
Services registered sales (39.5% of net sales) worth $261.2 million, climbing a mere 0.2% year over year and 3% at cc.
Chemistry sales (20.8% of net sales) were $137.6 million, growing 2.6% year over year and 5% at cc.
The Services and Chemistry segments jointly generated recurring revenues of $398.8 million, up 1% year over year and 4% at cc.
Markets: Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic.
The Pharmaceutical market (59.1% of net sales) generated sales of $391.1 million, which increased 4.5% on a year-over-year and 8% at cc.
The Industrial market’s (27.5% of net sales) sales were $203.4 million, up 4.1% year over year and 6% at cc.
The Government & Academic market (10.2% of net sales) generated $67.3 million in sales, which remained flat year over year and increased 3% at cc.
Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia (33.4% of net sales) generated $220.8 million in sales, up 6.4% and 13% on a year-over-year and cc basis, respectively.
Sales in the Americas (38.6% of net sales) generated $255.5 million, which increased 6% in both year-over-year and cc terms.
Europe (28% of net sales) generated $185.4 million in sales, which decreased 1.4% year over year but increased 1% at cc.
WAT’s Q1 Operating Details
In the first quarter of 2025, non-GAAP selling and administrative expenses were $170.1 million, up 6% year over year. As a percentage of net sales, the figure expanded 50 basis points (bps) on a year-over-year basis.
Research and development spending of $46 million increased 7.7% year over year. As a percentage of net sales, the figure expanded 20 bps year over year.
The adjusted operating margin was 25.5%, which contracted 150 bps year over year.
Waters Balance Sheet & Cash Flow
As of March 29, 2025, cash, cash equivalents were $382.9 million, up from $325.4 million as of Dec. 31, 2024.
Waters generated cash from operations of $259.6 million in the reported quarter, down from $262.9 million in the year-ago quarter.
WAT recorded a free cash flow of $233.8 million in the first quarter of 2025.
WAT Raised Guidance
For the second quarter of 2025, Waters expects non-GAAP earnings of $2.88-$2.98 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
The Zacks Consensus Estimate for earnings is pegged at $2.93 per share, down by a penny over the past 30 days but indicates 11.4% growth from the figure reported in the year-ago quarter.
Waters anticipates sales to grow 5-7% on a cc basis after adequately discounting recent policy developments in the United States.
On a reported basis, total sales growth is predicted to be in the range of 4-6% backed by the strong first quarter and tailwinds from favorable forex.
The Zacks Consensus Estimate for revenues is pegged at $746.9 million, suggesting 5.42% year-over-year growth.
For 2025, Waters anticipates non-GAAP earnings between $12.75 per share and $13.05 per share.
The Zacks Consensus Estimate for earnings is pegged at $12.85 per share, up by a penny over the past 30 days, indicating an 8.4% increase from the figure reported in 2024.
On a reported basis, total sales are suggested to improve by 4.0 – 6.0% while at cc sales is expected to increase between 5% and 7%.
Waters Zacks Rank & Stocks to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
ANI Pharmaceuticals (ANIP - Free Report) , Acurx Pharmaceuticals (ACXP - Free Report) , and Agenus (AGEN - Free Report) are some better-ranked stocks in the broader Zacks Medical sector. Each of the three stocks carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ANI Pharmaceuticals is set to report its first-quarter 2025 results on May 9. Acurx Pharmaceuticals is set to report first-quarter 2025 results on May 13. Agenus is set to report its first-quarter 2025 results on May 12.